drugset / Trial / NCT06359600
A Study of HS-10501 Tablets in Healthy Subjects
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single dose and multiple dose of HS-10501 tables in healthy subjects. This is the first clinical study of HS-10501 tables. This study has 2 parts. Parts A involve a single dose of HS-10501 tables or placebo and will last about 8 days. Also, this part will also further explore the food effect. Parts B involve multiple doses of HS-10501 tables or placebo and will last about 4 weeks.
Timeline
- Start
- 2024-03-14
- Primary completion
- 2025-01-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10501 | Unknown | — | Oral |
Indications
No indication recorded.